Dermata Therapeutics Statistics
Share Statistics
Dermata Therapeutics has 2.04M shares outstanding. The number of shares has increased by -57.33% in one year.
| Shares Outstanding | 2.04M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 240.09% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.01M |
| Failed to Deliver (FTD) Shares | 17 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 93.74K, so 4.59% of the outstanding shares have been sold short.
| Short Interest | 93.74K |
| Short % of Shares Out | 4.59% |
| Short % of Float | 4.68% |
| Short Ratio (days to cover) | 0.52 |
Valuation Ratios
The PE ratio is -0.23 and the forward PE ratio is -0.33.
| PE Ratio | -0.23 |
| Forward PE | -0.33 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.28 |
| P/FCF Ratio | -0.28 |
| PEG Ratio | n/a |
Enterprise Valuation
Dermata Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 4.91, with a Debt / Equity ratio of 0.
| Current Ratio | 4.91 |
| Quick Ratio | 4.91 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.23% and return on capital (ROIC) is -126.54%.
| Return on Equity (ROE) | -1.23% |
| Return on Assets (ROA) | -0.98% |
| Return on Capital (ROIC) | -126.54% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -974.34K |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -89.37% in the last 52 weeks. The beta is 0.79, so Dermata Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.79 |
| 52-Week Price Change | -89.37% |
| 50-Day Moving Average | 1.3 |
| 200-Day Moving Average | 3.31 |
| Relative Strength Index (RSI) | 41.25 |
| Average Volume (20 Days) | 680.07K |
Income Statement
In the last 12 months, Dermata Therapeutics had revenue of $0 and earned -$7.79M in profits. Earnings per share was $-40.18.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -8.04M |
| Net Income | -7.79M |
| EBITDA | 247.22K |
| EBIT | - |
| Earnings Per Share (EPS) | -40.18 |
Balance Sheet
The company has $7.44M in cash and $0 in debt, giving a net cash position of $7.44M.
| Cash & Cash Equivalents | 7.44M |
| Total Debt | 0 |
| Net Cash | 7.44M |
| Retained Earnings | -53.39M |
| Total Assets | 6.69M |
| Working Capital | 4.74M |
Cash Flow
In the last 12 months, operating cash flow was -$6.41M and capital expenditures $0, giving a free cash flow of -$6.41M.
| Operating Cash Flow | -6.41M |
| Capital Expenditures | 0 |
| Free Cash Flow | -6.41M |
| FCF Per Share | -33.04 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
DRMA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -3652.73% |
| FCF Yield | -285.5% |
Analyst Forecast
The average price target for DRMA is $6, which is 445.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $6 |
| Price Target Difference | 445.5% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on May 16, 2024. It was a backward split with a ratio of 1:15.
| Last Split Date | May 16, 2024 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -18.3 |
| Piotroski F-Score | 2 |